Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia.
Our objective was to investigate the prognostic significance of serum beta-2 microglobulin (B2M) levels among patients with chronic myelogenous leukemia (CML). All patients with Philadelphia chromosome-positive early chronic phase CML (i.e., within 1 year of diagnosis) treated with IFN alpha-based therapy at the M. D. Anderson Cancer Center between 1980 and 1997, in whom pretreatment B2M levels were available, were investigated. Two hundred one patients were evaluable. Their median B2M was 2.2 mg/dl (range, 1.1-20 mg/dl). Serum B2M levels were associated with other variables of prognostic significance, including age, spleen size, WBC count, percentage of peripheral and marrow blasts, and percentage of marrow basophils. Patients with B2M levels >2.9 mg/dl (ie., the upper quartile of the distribution) had a significantly lower rate of major cytogenetic response compared to those in the lower three quartiles (20 versus 52%; P < 0.01). They also had a shorter survival, with a 5-year survival rate of 48%, compared with 75% for those in the lower quartiles (P = 0.01). High B2M levels (>2.9 mg/dl) could identify a group of patients with an adverse outcome within patients in stage I disease (P = 0.02). Results for patients in stages 2-4 were inconclusive because of the small number of patients in these groups. We conclude that serum B2M levels are an important, and probably independent, prognostic factor for patients with CML in early chronic phase treated with IFN-based therapy.
Rodriguez
J
J
Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Cortes
J
J
Talpaz
M
M
O'Brien
S
S
Smith
T L
TL
Rios
M B
MB
Kantarjian
H
H
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D003561:Cytarabine / Q000627:therapeutic use; D018572:Disease-Free Survival; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007370:Interferon Type I / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D007371:Interferon-gamma / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood* / Q000188:drug therapy / Q000401:mortality*; D008875:Middle Aged; D011379:Prognosis; D011994:Recombinant Proteins; D015996:Survival Rate; D013997:Time Factors; D001613:beta 2-Microglobulin / Q000097:blood*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins; D001613:beta 2-Microglobulin; D003561:Cytarabine; D007371:Interferon-gamma; D006918:Hydroxyurea